新規GVHD 診断マーカー ―その臨床応用の可能性―

概要

論文の詳細を見る
Although graft-versus-host disease (GVHD) is a life- threatening complication of hematopoietic stem cell transplantation (HSCT), current diagnosis mainly depends on clinical manifestations and invasive biopsies. Specific biomarkers for GVHD would facilitate early and accurate recognition of this grave condition. Using a proteomic approach, we screened for plasma proteins specific for GVHD in a mouse model. One peak with 8,972 m/z retained a discriminatory value in two diagnostic groups (GVHD and normal controls) with increased expression in the disease, decreased expression during cyclosporin A treatment and was barely detectable in syngeneic transplantation. Purification and mass analysis identified this molecule as CCL8, a member of a large chemokine family. In human samples, the serum concentration of CCL8 correlated closely with GVHD severity. All non-GVHD samples had low levels of CCL8. In sharp contrast, CCL8 was highly up-regulated in GVHD sera. CCL8 is a promising specific serum marker for the early and accurate diagnosis of GVHD.
札幌医科大学の論文